Hematology & Oncology Headlines


Alok Khorana, MD: Prophylactic Treatment With Rivaroxaban Reduces Cancer Patients’ VTE Risk

Patients with cancer are at an increased risk of blood clots. Research presented at the 2018 ASH Annual Meeting showed that rivaroxaban reduced the risk of venous thromboembolism (VTE) in patients with cancer who...

#ASH18 Conference Coverage

Latest Abstracts

This Week`s Featured Journal: ASH Clinical News

Conversations with Experts

click me